Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
Michael Michael, Peter Gibbs, Robert Smith, Alex Godwood, Stuart Oliver, Niall Tebbutt
INVESTIGATIONAL NEW DRUGS | SPRINGER | Published : 2009
BACKGROUND: Vandetanib (ZACTIMA) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients with advanced colorectal cancer (CRC). METHODS: Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of mFOLFOX6. RESULTS: Seventeen patients received vandetanib 100 mg (n = 9) or 300 mg (n = 8) plus mFOLFOX6. The protocol definition of a tolerable dose (vandetanib-related dose-limiting toxicity [DLT] in less than two patients) was met in both dose cohorts,..View full abstract
This study, including editorial assistance provided by Chris Watson of Mudskipper Bioscience, was supported financially by AstraZeneca. ZACTIMA is a trademark of the AstraZeneca group of companies.